Endotoxin tolerance does not limit mild ischemia-reperfusion injury in humans in vivo

Innate Immunity

Volumn 15, Issue 6, 2009, Pages 360-367

  Draisma, Annelies ^a   De Goeij, Moniek ^a   Wouters, Constantijn W ^a   Riksen, Niels P ^a   Oyen, Wim J G ^a   Rongen, Gerard A ^a   Boerman, Otto C ^a   Van Deuren, M ^a   Van Der Hoeven, Johannes G ^a   Pickkers, Peter ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Annexin a5 scintigraphy; Cross tolerance; Endotoxin tolerance; Human endotoxemia; Ischemia reperfusion injury

Indexed keywords

COMPLEMENT COMPONENT C3B; ESCHERICHIA COLI ENDOTOXIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; LIPOCORTIN 5; PHOSPHATIDYLSERINE; TECHNETIUM 99M;

ADULT; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; EXERCISE; FOREARM BLOOD FLOW; HAND GRIP; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; ISCHEMIA; PROTEIN EXPRESSION; RADIOACTIVITY; REPERFUSION INJURY; SCINTIGRAPHY; THENAR; VEIN OCCLUSION;

ADULT; CYTOKINES; ENDOTOXEMIA; HUMANS; LIPOPOLYSACCHARIDES; MALE; REPERFUSION INJURY; TECHNETIUM;

ANIMALIA;

EID: 74549156299     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425909105548     Document Type: Article

References (44)

1. Berry LJ, Smythe DS. Some metabolic aspects of tolerance to bacterial endotoxin. J Bacteriol 1965; 90: 970-977.
2. Brooke MS. Conversion of immunological paralysis to immunity by endotoxin. Nature 1965; 206: 635-636.
3. Golub ES, Weigle WO. Studies on the induction of immunologic unresponsiveness. 3. Antigen form and mouse strain variation. J Immunol 1969; 102: 389-396.
4. Greisman SE, Young EJ, Carozza Jr FA. Mechanisms of endotoxin tolerance. V. Specificity of the early and late phases of pyrogenic tolerance. J Immunol 1969; 103: 1223-1236.
5. Greisman SE, Hornick RB. Mechanisms of endotoxin tolerance with special reference to man. J Infect Dis 1973; 128 (Suppl): 265-276.
6. Milner KC. Patterns of tolerance to endotoxin. J Infect Dis 1973; 128 (Suppl): 237-245.
7. Neter E. Endotoxins and the immune response. Curr Top Microbiol Immunol 1969; 47: 82-124.
8. Draisma A, Pickkers P, Bouw MP, van der Hoeven JG. Development of endotoxin tolerance in humans in vivo. Crit Care Med 2009; 37: 1261-1267.
9. 9. Ackermann M, Reuter M, Flohe S, Bahrami S, Redl H, Schade FU. Cytokine synthesis in the liver of endotoxin-tolerant and normal rats during hemorrhagic shock. J Endotoxin Res 2001; 7: 105-112. (Pubitemid 32677607)
10. 10. Barroso-Aranda J, Chavez-Chavez RH, Mathison JC, Suematsu M, Schmid-Schonbein GW. Circulating neutrophil kinetics during tolerance in hemorrhagic shock using bacterial lipopolysaccharide. Am J Physiol 1994; 266: H415-H421. (Pubitemid 24104782)
11. 11. Ahmed SH, He YY, Nassief A et al. Effects of lipopolysaccharide priming on acute ischemic brain injury. Stroke 2000; 31: 193-199. (Pubitemid 30035774)
12. 12. Bordet R, Deplanque D, Maboudou P et al. Increase in endogenous brain superoxide dismutase as a potential mechanism of lipopolysaccharide-induced brain ischemic tolerance. J Cereb Blood Flow Metab 2000; 20: 1190-1196. (Pubitemid 30636754)
13. 13. Dawson DA, Furuya K, Gotoh J, Nakao Y, Hallenbeck JM. Cerebrovascular hemodynamics and ischemic tolerance: lipopolysaccharide-induced resistance to focal cerebral ischemia is not due to changes in severity of the initial ischemic insult, but is associated with preservation of microvascular perfusion. J Cereb Blood Flow Metab 1999; 19: 616-623. (Pubitemid 30161213)
14. 14. Rosenzweig HL, Lessov NS, Henshall DC, Minami M, Simon RP, Stenzel-Poore MP. Endotoxin preconditioning prevents cellular inflammatory response during ischemic neuroprotection in mice. Stroke 2004; 35: 2576-2581. (Pubitemid 39458420)
15. 15. Tasaki K, Ruetzler CA, Ohtsuki T, Martin D, Nawashiro H, Hallenbeck JM. Lipopolysaccharide pre-treatment induces resistance against subsequent focal, cerebral ischemic damage in spontaneously hypertensive rats. Brain Res 1997; 748: 267-270. (Pubitemid 27094913)
16. Brown JM, Grosso MA, Terada LS et al. Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc Natl Acad Sci USA 1989; 86:2516-2520.
17. 17. Eising GP, Mao L, Schmid-Schonbein GW, Engler RL, Ross J. Effects of induced tolerance to bacterial lipopolysaccharide on myocardial infarct size in rats. Cardiovasc Res 1996; 31: 73-81. (Pubitemid 26093057)
18. 18. Yao Z, Auchampach JA, Pieper GM., Gross GJ. Cardioprotective effects of monophosphoryl lipid A, a novel endotoxin analogue, in the dog. Cardiovasc Res 1993; 27: 832-838. (Pubitemid 23162681)
19. Colletti LM, Remick DG, Campbell Jr DA. LPS pretreatment protects from, hepatic ischemia/reperfusion. J Surg Res 1994; 57: 337-343.
20. Dominguez FE, Siemers F, Flohe S, Nau M, Schade FU. Effects of endotoxin tolerance on liver function after hepatic ischemia/ reperfusion injury in the rat. Crit Care Med 2002; 30: 165-170. (Pubitemid 34112192)
21. Fernandez ED, Flohe S, Siemers F et al. Endotoxin tolerance protects against local hepatic ischemia/reperfusion injury in the M. J Endotoxin Res 2000; 6: 321-328. (Pubitemid 32140714)
22. 22. Yoshidome H, Kato A, Edwards MJ, Lentsch AB. Interleukin-10 suppresses hepatic ischemia/reperfusion injury in mice: implications of a central role for nuclear factor kappaB. Hepatology 1999; 30: 203-208. (Pubitemid 29300587)
23. Obermaier R, Drognitz O, Grub A et al. Endotoxin preconditioning in pancreatic ischemia/reperfusion injury. Pancreas 2003; 27: e51-e56.
24. 24. Friedrich I, Spillner J, Lu EX et al. Induction of endotoxin tolerance improves lung function after warm ischemia in dogs. Am J Physiol 2003; 284: L224-L231. (Pubitemid 35471275)
25. 25. Markart P, Schmidt R, Ruppert C et al. Ischemic and endotoxin pre-conditioning reduce lung reperfusion injury-induced surfactant alterations. J Heart Lung Transplant 2005; 24: 1680-1689. (Pubitemid 41396470)
26. 26. Godet C, Goujon JM, Petit I et al. Endotoxin tolerance enhances interleukin-10 renal expression and decreases ischemia-reperfusion renal injury in rats. Shock 2006; 25: 384-388. (Pubitemid 43755938)
27. 27. Heemann U, Szabo A, Hamar P et al. Lipopolysaccharide pretreatment protects from renal ischemia/reperfusion injury; possible connection to an interleukin-6-dependent pathway. Am J Pathol 2000; 156: 287-293. (Pubitemid 30644462)
28. Yellon DM, Hausenloy DJ. Myocardial, reperfusion injury. N Engl J Med 2007; 357: 1121-1135.
29. Rongen GA, Oyen WJ, Ramákers BP et al. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation 2005; 111: 173-178.
30. 30. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van, Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-1420. (Pubitemid 24273007)
31. Riksen NP, Oyen WJ, Ramakers BP et al. Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. Clin Pharmacol Ther 2005; 78: 52-59.
32. 32. Riksen NP, Zhou Z, Oyen WJ et al. Caffeine prevents protection in two human models of ischemic preconditioning. J Am Coll Cardiol 2006; 48: 700-707. (Pubitemid 44175737)
33. 33. Dorresteijn MJ, van, Eijk LT, Netea MG, Smits P, van der Hoeven JG, Pickkers P. Iso-osmolar prehydration shifts the cytokine response towards a more anti-inflammatory balance in human endotoxemia. J Endotoxin Res 2005; 11: 287-293. (Pubitemid 41556036)
34. 34. Dorresteijn MJ, Pickkers P, Netea MG, van der Hoeven JG. IFNgamma is not induced through increased plasma concentrations of interleukin-12/ interleukin-18 during human endotoxemia. Eur Cytokine Netw 2005; 16: 191-193. (Pubitemid 46638749)
35. 35. Pickkers P, Dorresteijn MJ, Bouw MP, van der Hoeven JG, Smits P. In vivo evidence for nitric oxide-mediated calciumactivated potassium-channel activation during human endotoxemia. Circulation 2006; 114: 414-421. (Pubitemid 44264823)
36. van, Eijk LT, Pickkers P, Smits P, van, den BW, Bouw MP, van der Hoeven JG. Microvascular permeability during experimental human endotoxemia: an open intervention study. Crit Care 2005; 9: R157-R164.
37. 37. van, Eijk LT, Nooteboom. A, Hendriks T et al. Plasma obtained during human endotoxemia increases endothelial albumin permeability in vitro. Shock 2006; 25: 358-362. (Pubitemid 43755934)
38. 38. van, Eijk LT, Dorresteijn MJ, Smits P, van der Hoeven JG, Netea MG, Pickkers P. Gender differences in the innate immune response and vascular reactivity following the administration of endotoxin to human volunteers. Crit Care Med 2007; 35: 1464-1469. (Pubitemid 46809308)
39. 39. Schreiber-Deturmeny E, Bruguerolle B. Simultaneous highperformance liquid chromatographic determination of caffeine and theophylline for routine drug monitoring in human plasma. J Chromatogr B Biomed Appl 1996; 677: 305-312. (Pubitemid 26105999)
40. 40. Garred P, Mollnes TE, Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol 1988; 27: 329-335. (Pubitemid 18076757)
41. 41. Mollnes TE, Lea T, Froland SS, Harboe M. Quantification of the terminal complement complex in human plasma by an enzymelinked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985; 22: 197-202. (Pubitemid 15016794)
42. 42. Szabo A, Heemann U. Ischemia reperfusion injury and chronic allograft rejection. Transplant Proc 1998; 30: 4281-4284. (Pubitemid 29013225)
43. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003; 83: 1113-1151.
44. Hammill AK, Uhr JW, Scheuermann RH. Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death. Exp Cell Res 1999; 251: 16-21.